REGEN Capital

What REGEN Capital does

REGEN Capital is a Toronto-based early-stage venture capital firm founded in 2018 that invests equity capital in frontier-technology companies across North America. The fund targets pre-seed through early-stage companies in biotechnology, fintech, artificial intelligence, quantum computing, diagnostics, healthcare services, healthcare IT, and real estate, deploying initial cheques of $50,000 to $250,000 and taking board seats in portfolio companies. Its brand and deal sourcing are anchored by Managing Director Dr. Riam Shammaa, a physician-researcher who founded the Canadian Centre for Regenerative Therapy (CCRT) — the first recognized private cell therapy centre in Canada — as well as clinical-stage operating companies CELL, Intellistem, and Freyja Therapeutics, and who holds multiple patents in regenerative and translational medicine. The firm has assembled a four-person investment team, supplements its own deal flow with a co-investor network and strategic partners (Kraft Berger LLP, Dentons, Natural Products Canada), and has reported exits via acquisitions of portfolio companies Cybeats and OnCall.

The firm operates as a classic early-stage equity investor rather than a product or SaaS business: returns are generated through portfolio company exits, acquisitions, and IPOs rather than subscription or transaction fees on its own technology. Investment selection emphasizes sectors where the team's regenerative-medicine and operating expertise provides informational advantage, and where co-investor networks can supplement small initial tickets. The firm's risk profile is that of a sub-$25M emerging manager: limited disclosed AUM, small team, narrow public presence (website news content last updated 2019), and a portfolio that is heavily concentrated in companies affiliated with the founding GP, which simultaneously creates alignment and concentration risk.

Name

REGEN Capital

Legal name

Regen Capital

Website

https://regencapital.org

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

REGEN Capital is a Toronto-based early-stage venture capital firm founded in 2018 that invests $50,000–$250,000 equity cheques in frontier-technology startups across biotechnology, fintech, AI, quantum computing, healthcare, and real estate throughout North America.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Other Financial Investment Activities (5239), Funds, Trusts, and Other Financial Vehicles (525), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

Keywords

• Venture capital investing
• Early stage funding
• Frontier technology investment
• Startup equity investment
• Healthcare venture capital

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Venture Capital Returns: Regen Capital generates returns through equity investments in early stage companies. They invest $50,000 to $250,000 initial cheque sizes with allocation for follow-up rounds. Returns realized through portfolio company exits, acquisitions, and IPOs.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

REGEN Capital is an early-stage venture fund that makes equity investments of USD 50,000 to USD 250,000 (with follow-on capacity) into pre-seed through early-stage frontier technology companies across North America. The firm leads investment rounds, takes board seats, and provides hands-on strategic and operational support through its co-investor network and strategic partners, focusing on biotechnology, fintech, artificial intelligence, quantum computing, diagnostics, healthcare services, healthcare IT, and real estate.

Product overview

REGEN Capital is an early-stage venture capital firm that invests in frontier technology companies across North America. Rather than offering a unified software product platform, the firm provides venture capital investment services with board participation, targeting pre-seed to early-stage companies in biotechnology, financial technology, artificial intelligence, quantum computing, diagnostics, healthcare services, healthcare IT, and real estate. The firm's investment range spans $50,000 to $250,000 per company.

Differentiator

Problem solved

Functional benefit

Products and services

• Early-Stage Equity Investment Equity investment product offering USD 50,000 to USD 250,000 initial cheques with follow-on capacity into pre-seed through early-stage frontier technology start-ups in biotechnology, fintech, AI, quantum computing, diagnostics, healthcare services, healthcare IT, and real estate, including leading rounds, taking board seats, and providing hands-on strategic and operational support.

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered minor.

• Kraft Berger LLPminorImplementation/ SI/ Consulting PartnerLegal and advisory partner listed on the Partners & Advisors section of the Regen Capital website
• Natural Products CanadaminorStrategic or Co-development PartnerStrategic partner in the natural products industry ecosystem, listed on Partners & Advisors section
• DentonsminorImplementation/ SI/ Consulting PartnerGlobal law firm advisory partner listed on Partners & Advisors section of the Regen Capital website

Scale indicators3 records

Recent moves2 records

Expansion highlights5 records

Direct peers

• Genesys Capital: Toronto-based Canadian healthcare- and biotech-focused VC. Comparable on geography and biotech/healthcare specialist thesis — directly relevant to Regen's regenerative-medicine affiliations.
• Amplitude Ventures: Canadian healthcare- and biotech-focused VC backing precision medicine and health-tech startups. Comparable on Canadian presence and biotech/healthcare thesis overlap with Regen's clinical-stage subsidiaries.
• TandemLaunch: Montreal-based deep-tech seed fund backing founders commercializing university and corporate IP. Comparable on Canadian presence, seed-stage approach, and frontier-tech thesis (AI/quantum/biotech).
• Real Ventures: Montreal-based early-stage VC investing across multiple frontier-tech and digital health verticals in Canada. Most directly comparable peer — Canadian early-stage multi-vertical VC with a similarly broad thesis across emerging tech.
• iGan Partners: Toronto-based early-stage VC focused exclusively on health-tech and medical-tech companies. Comparable as a Canadian early-stage healthcare specialist with overlap on the regenerative-medicine / health-tech thesis.
• Panache Ventures: Montreal/Toronto early-stage VC backing pre-seed and seed Canadian tech startups across sectors. Closely comparable on stage (pre-seed/seed), geography (Canadian), and multi-sector thesis.
• Loyal VC: Toronto-based pre-seed VC investing in Canadian tech startups via a rolling fund structure. Comparable on stage, Canadian geography, and small-team operating model.
• Version One Ventures: Vancouver-based early-stage VC backing mission-driven founders across consumer, enterprise, and frontier tech. Comparable on stage, Canadian footprint, and broad thematic mandate.

Broad incumbents

• Georgian Partners: Toronto-based growth-stage VC focused on applied AI, fintech, and software. Comparable as a Canadian multi-vertical tech investor, but operates at Series B+ stage with significantly larger AUM — a broad incumbent rather than a direct stage competitor.
• Inovia Capital: One of Canada's largest and most established VC firms investing across enterprise SaaS, consumer, fintech, and emerging tech. Comparable on Canadian footprint and multi-vertical tech thesis, but operates at meaningfully larger scale and cheque size.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/regen-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REGEN Capital